[1] Abbas AR, Baldwin D, Ma Y, et al.Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data[J]. Genes Immun,2005,6(4):319-331. [2] Yu X, Harden K, Gonzalez LC, et al.The surface protein TIGIT suppresses T cell activation by promoting the gene-ration of mature immunoregulatory dendritic cells[J]. Nat Immunol,2009,10(1):48-57. [3] Kourepini E, Paschalidis N, Simoes DC, et al.TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease[J]. J Immunol,2016,196(9):3570-3580. [4] Joller N, Lozano E, Burkett PR, et al.Treg cells expres-sing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses[J]. Immunity,2014,40(4):569-581. [5] Anderson AC, Joller N, Kuchroo VK.Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation[J]. Immunity,2016,44(5):989-1004. [6] Johnston RJ, Comps-Agrar L, Hackney J, et al.The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function[J]. Cancer Cell,2014,26(6):923-937. [7] Wang X, Ma Z, Hong Y, et al.The skewed TCR-BV repertoire displayed at the maternal-fetal interface of women with unexplained pregnancy loss[J]. Am J Reprod Immunol,2005,54(2):84-95. [8] Wang SC, Li YH, Piao HL, et al.PD-1 and Tim-3 pathways are associated with regulatory CD8+ T-cell function in decidua and maintenance of normal pregnancy[J]. Cell Death Dis,2015,6:e1738. [9] 林其德. 原因不明复发性流产的基础与临床研究进展[J]. 中华妇产科杂志,2003,38(8):481-483. [10] Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acidScience,2007,317(5835):256-260. [11] Wu L, Luo LH, Zhang YX, et al.Alteration of Th17 and Treg cells in patients with unexplained recurrent spontaneous abortion before and after lymphocyte immunization therapy[J]. Reprod Biol Endocrinol,2014,12:74. [12] 张建平. NK细胞与复发性自然流产母胎免疫紊乱[J]. 中山大学学报(医学科学版),2010,31(4):451-456,481. [13] Mahnke K, Enk AH.TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention[J]. J Invest Dermatol,2016,136(1):9-11. [14] Pauken KE, Wherry EJ.TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit[J]. Cancer Cell,2014,26(6):785-787. [15] Lozano E, Dominguez-Villar M, Kuchroo V, et al.The TIGIT/CD226 axis regulates human T cell function[J]. J Immunol,2012,188(8):3869-3875. |